MVASI® (Bevacizumab-awwb)

The FDA on September 14, 2017 approved MVASI® as a biosimilar to AVASTIN® (Bevacizumab). MVASI® is the first biosimilar approved in the U.S. for the treatment of cancer, and is a product of Amgen Inc.